PCM
NGM

Prelude Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Prelude Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,416
Closed -$27K – 1436
2023
Q2 		$27K Buy
+10,416
New +$37.2K ﹤0.01% 1003
2019
Q4 		– Sell
-20,435
Closed -$283K – 2337
2019
Q3 		$283K Buy
+20,435
New +$307K 0.01% 679

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's NGM Position: Q3 2023 in Review

Prelude Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 10,416 shares — an estimated $27K sold.

Prelude Capital Management first reported a position in NGM in Q3 2019 and held it in 2 quarters. The position peaked at $283K in Q3 2019. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • Prelude Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 10,416 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $27K.
  • Prelude Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Prelude Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $283K in Q3 2019.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.